Extended Follow Up of KEYNOTE-B61

Author(s):

Martin H. Voss, MD, provides an update on the extended follow-up data from the phase 2 KEYNOTE-B61 study, which investigates the efficacy and safety of combination therapy consisting of pembrolizumab and lenvatinib as a first-line treatment option for patients with advanced non-clear cell renal cell carcinoma.

EP: 1.Evolving Treatment Standards in Non-Clear Cell RCC

Now Viewing

EP: 2.Extended Follow Up of KEYNOTE-B61

Please discuss extended follow up from the phase 2 KEYNOTE-B61 study investigating pembrolizumab + lenvatinib in the first-line treatment of advanced non-clear cell RCC. (Voss M et al. ASCO GU 2024, Abstract #2)
Please provide a brief background surrounding KEYNOTE-B61 (Albiges, et al. Lancet Oncol, 2023)
How did the response rates compare across histologies?
Considering the observed OS benefit with adjuvant pembro, do you intend to approach its adjuvant use in a similar or different manner in this treatment setting?